Regulus Therapeutics Inc. (NASDAQ:RGLS) Ratings Summary on Jun 27, 2018

June 27, 2018 - By Stephany Jackson

Regulus Therapeutics Inc. (NASDAQ:RGLS) Corporate Logo
During 2018 Q1 the big money sentiment decreased to 1.11. That’s change of 0.05, from 2017Q4’s 1.16. 8 investors sold all, 10 reduced holdings as Regulus Therapeutics Inc. ratio turned negative. 11 grew holdings while 9 funds amassed holdings. Funds hold 50.71 million shares thus 4.62% less from 2017Q4’s 53.17 million shares.
Fmr Limited Liability Corp stated it has 15.59M shs or 0% of all its holdings. California Pub Employees Retirement Systems holds 177,600 shs or 0% of its capital. Alpine Glob Ltd Co holds 10,223 shs or 0% of its capital. Macquarie Grp owns 20,000 shs. Fincl Bank Of New York Mellon Corporation owns 0% invested in Regulus Therapeutics Inc. (NASDAQ:RGLS) for 67,448 shs. Bnp Paribas Arbitrage Sa owns 4 shs. Vanguard Group Inc Inc owns 2.78M shs. Mariner Ltd Com accumulated 0% or 15,545 shs. Virtu Lc, New York-based fund reported 78,587 shs. Point72 Asset Management Limited Partnership invested 0% in Regulus Therapeutics Inc. (NASDAQ:RGLS). State Street Corp invested in 0% or 56,779 shs. Hightower Advisors Ltd Liability Corp has 22,475 shs. Millennium Mngmt Limited Liability Company holds 0% or 109,993 shs. Nea Communication Ltd Company owns 10.99M shs. Utd Automobile Association owns 33,260 shs.

Regulus Therapeutics Inc. (NASDAQ:RGLS) Ratings Coverage

Total analysts of 5 have positions in Regulus Therapeutics (NASDAQ:RGLS) as follows: 2 rated it a “Buy”, 0 with “Sell” and 3 with “Hold”. The positive are 40%. Since January 5, 2018 according to StockzIntelligence Inc Regulus Therapeutics has 7 analyst reports. On Thursday, February 8 the company was maintained by Wedbush. The stock rating was initiated by FBR Capital with “Hold” on Tuesday, March 27. On Monday, March 12 the rating was maintained by Wedbush with “Buy”. On Thursday, March 8 the stock of Regulus Therapeutics Inc. (NASDAQ:RGLS) earned “Market Perform” rating by BMO Capital Markets. On Thursday, May 17 the rating was maintained by Wedbush with “Buy”. Listed here are Regulus Therapeutics Inc. (NASDAQ:RGLS) PTs and latest ratings.

17/05/2018 Broker: Wedbush Rating: Buy New Target: $3.0000 Maintain
28/03/2018 Broker: B. Riley & Co Rating: Neutral New Target: $1 Initiates Coverage On
27/03/2018 Broker: FBR Capital Rating: Hold New Target: $1.0000 Initiate
12/03/2018 Broker: Wedbush Rating: Buy New Target: $3.0 Maintain
08/03/2018 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Market Perform Old Target: $1 New Target: $1.37 Maintain
08/02/2018 Broker: Wedbush Rating: Buy New Target: $4.0 Maintain
05/01/2018 Broker: Leerink Swann Rating: Outperform New Target: $2 Initiates Coverage On

Ticker’s shares touched $0.66 during the last trading session after 0.60% change.Since June 27, 2017 it’s 45.33% down thus downtrending. The stock underperformed the S&P 500 by 57.90%.

Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States.The firm is worth $68.85 million. The firm uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides.Currently it has negative earnings. The Company’s clinical development products include RG-101, a GalNAc-conjugated anti-miR targeting miR-122 to treat patients with hepatitis C virus infection; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome; RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107 for the treatment of non-alcoholic fatty liver disease; RGLS5040, an anti-miR targeting microRNA-27 for the treatment of cholestatic disease; and RGLS4326, an anti-miR targeting microRNA-17 for the treatment of autosomal dominant polycystic kidney disease.

There’s a significant Regulus Therapeutics Inc. (NASDAQ:RGLS) news released by Nasdaq.com. It’s a report titled: “New Research: Key Drivers of Growth for CNA Financial, AutoNation, Hess, Infinity Pharmaceuticals, Regulus …” on June 12, 2018.

Regulus Therapeutics Inc. (NASDAQ:RGLS) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: